GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (LTS:0MTD) » Definitions » Return-on-Tangible-Asset

Swedish Orphan Biovitrum AB (LTS:0MTD) Return-on-Tangible-Asset : 23.45% (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Swedish Orphan Biovitrum AB's annualized Net Income for the quarter that ended in Mar. 2024 was kr3,200 Mil. Swedish Orphan Biovitrum AB's average total tangible assets for the quarter that ended in Mar. 2024 was kr13,646 Mil. Therefore, Swedish Orphan Biovitrum AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 23.45%.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Return-on-Tangible-Asset or its related term are showing as below:

LTS:0MTD' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -13.37   Med: 27.66   Max: 43.28
Current: 16.94

During the past 13 years, Swedish Orphan Biovitrum AB's highest Return-on-Tangible-Asset was 43.28%. The lowest was -13.37%. And the median was 27.66%.

LTS:0MTD's Return-on-Tangible-Asset is ranked better than
92.98% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs LTS:0MTD: 16.94

Swedish Orphan Biovitrum AB Return-on-Tangible-Asset Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Return-on-Tangible-Asset Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.28 36.59 27.16 23.22 18.26

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.49 7.50 3.09 31.37 23.45

Competitive Comparison of Swedish Orphan Biovitrum AB's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Return-on-Tangible-Asset falls into.



Swedish Orphan Biovitrum AB Return-on-Tangible-Asset Calculation

Swedish Orphan Biovitrum AB's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=2409/( (12483+13907)/ 2 )
=2409/13195
=18.26 %

Swedish Orphan Biovitrum AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=3200/( (13907+13385)/ 2 )
=3200/13646
=23.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Swedish Orphan Biovitrum AB  (LTS:0MTD) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Swedish Orphan Biovitrum AB Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (LTS:0MTD) Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (LTS:0MTD) Headlines

No Headlines